Prostate Cell News Volume 7.00 | Jan 8 2016

Histone Demethylase JMJD2A Drives Prostate Tumorigenesis through Transcription Factor ETV1
Scientist found that overexpression of lysine-specific demethylase 4A (KDM4A, also known as JMJD2A) was positively correlated with Gleason score and metastasis in human prostate tumors. Overexpression of JMJD2A resulted in the development of prostatic intraepithelial neoplasia in mice, demonstrating that JMJD2A can initiate prostate cancer development. [J Clin Invest] Full Article

An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers
To identify smoking-induced alterations in human prostate cancer, investigators analyzed gene and protein expression patterns in tumors collected from current, past, and never smokers. [Cancer Res] Abstract

Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant P53 in Prostate Cancer Cells
In prostate cancer (PCa) cells, there is CD24-dependent inactivation of mutant p53, but the mechanism and its significance remain largely unknown. Researchers validated this observation and explored the therapeutic potential of targeting CD24 in TP53 mutant PCa cells. [Clin Cancer Res] Abstract

Co-Targeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer
Scientists evaluated the efficacy and mechanism of combination therapy to block mTOR activity together with EPI-002, an AR N-terminal domain antagonist that blocks the transcriptional activities of full-length androgen receptor and androgen receptor splice variants in models of castration-resistant prostate cancer. [Clin Cancer Res] Abstract

Sildenafil (Viagra) Sensitizes Prostate Cancer Cells to Doxorubicin-Mediated Apoptosis through CD95
Scientists investigated the mechanism by which sildenafil sensitizes doxorubicin (DOX) in killing of prostate cancer (PCa) cells, DU145. The death receptor Fas (APO-1 or CD95) induces apoptosis in many carcinoma cells, which is negatively regulated by anti-apoptotic molecules such as FLIP (Fas-associated death domain (FADD) interleukin-1-converting enzyme (FLICE)-like inhibitory protein). [Oncotarget] Abstract | Full Article

Clonal Evaluation of Prostate Cancer Foci in Biopsies With Discontinuous Tumor Involvement by Dual ERG/SPINK1 Immunohistochemistry
Scientists hypothesized that spatially distinct prostate cancer foci in biopsies may arise from separate clones, impacting cancer involvement assessment. They used dual ERG/SPINK1 immunohistochemistry to determine the frequency of separate clones—when separate tumor foci showed discordant ERG and/or SPINK1 status—in discontinuously involved prostate biopsy cores from two academic institutions. [Mod Pathol] Abstract

Ad5/35E1aPSESE4: a Novel Approach to Marking Circulating Prostate Tumor Cells with a Replication Competent Adenovirus Controlled by PSA/PSMA Transcription Regulatory Elements
Investigators established a novel application for detecting PSA/PSMA-positive prostate cancer cells circulating in peripheral blood employing an adenovirus called Ad5/35E1aPSESE4. Ad5/35E1aPSESE4 utilized PSES, a chimeric enhancer derived from PSA/PSMA promoters that is highly active with and without androgen. [Cancer Lett] Abstract | Full Article 

Mitigation of Arsenic-Induced Acquired Cancer Phenotype in Prostate Cancer Stem Cells by miR-143 Restoration
Scientists investigated whether loss of miR-143 expression is important in arsenic-induced transformation of prostate stem/progenitor cells (SCs). Restoration of miR-143 in As-cancer stem cells (CSCs) was achieved by lentivirus-mediated miR-143 overexpression. [Toxicol Appl Pharmacol] Abstract

CLINICAL RESEARCH

Addition of Docetaxel or Bisphosphonates to Standard of Care in Men with Localised or Metastatic, Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analyses of Aggregate Data
Results from large randomised controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged. In order to investigate the effects of these therapies and to respond to emerging evidence, investigators aimed to systematically review all relevant trials using a framework for adaptive meta-analysis. [Lancet Oncol] Abstract | Full Article | Press Release

Prostate Cancer in Men of African Origin
Understanding differences in the cancer-survivorship experience and quality-of-life outcomes among men of African origin are critical to appropriately counsel patients and improve cultural sensitivity. Efforts to curtail prostate cancer screening will likely affect men of African origin disproportionately and widen the racial disparity of disease. [Nat Rev Urol] Abstract

Targeting Androgen/Estrogen Receptors Crosstalk in Cancer
Researchers discuss the molecular background regarding the therapeutic targeting of androgen/estrogen receptor crosstalk in breast and prostate cancer. [Trends Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

ImaginAb’s PSMA Imaging Agent Detects More Lesions Compared to Standard Imaging Methods for Detection of Prostate Cancer in Phase I/IIa Study
ImaginAb, Inc. announced clinical results from a Phase I/IIa trial of IAB2M, ImaginAb’s proprietary precision imaging agent for the detection of metastatic prostate cancer. In the study, IAB2M was able to detect bone lesions and soft-tissue lesions with far greater specificity and sensitivity than standard imaging methods. [Press release from ImaginAb, Inc. discussing research presented at the 2016 Genitourinary (GU) Cancers Symposium, San Francisco] Press Release

Circulating Tumor Cells Linked with Treatment Resistance and Response in Prostate Cancer Patients
Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies. [Press release from Epic Sciences discussing research presented at the 2016 Genitourinary (GU) Cancers Symposium, San Francisco] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

FDA Approved Investigational New Drug for NBTXR3 in a New Clinical Study in Prostate Cancer
NANOBIOTIX announces the US Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug application on the 30th of December. This allows Nanobiotix to launch its first clinical study in the United States for its lead product NBTXR3 in prostate cancer, a new and very significant indication. [NANOBIOTIX] Press Release

Acerus Receives Health Canada Approval For NATESTO™
Acerus Pharmaceuticals Corporation announced the Health Canada approval of NATESTO™, the first and only nasal gel for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). [Acerus Pharmaceuticals Corporation] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Faculty Position – Cancer Biology (Michigan State University )

NEW Post-Doc Fellowship – Cancer Stem Cell Biology (Weill Cornell Medical College)

Postdoctoral Position – Bioinformatics (Princess Margaret Cancer Centre)

Professorship – Oncogenic Pathways (German Cancer Research Center)

Professor Position – Cancer Immunotherapy (City of Hope)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Postdoctoral Positions – Prostate Cancer (Baylor College of Medicine)

Investigator – Cancer Biology (Wake Forest Baptist School of Medicine)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.